

New therapeutic strategies in the management of advanced-stage CTCL

Faculty

Ellen J. Kim, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Steven M. Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Larisa J. Geskin, MD, FAAD, Columbia University Medical Center, New York, NY, USA

Release date: March 10, 2021

Expiration date: March 10, 2022

Estimated time to completion: 1.0 hour

Available CME Credits: 1 AMA PRA Category 1 Credit(s)[™]

Activity description

Learn from leading experts as they provide commentaries on patient cases, highlighting current challenges and practical guidance in the management of advanced-stage cutaneous T-cell lymphoma (CTCL).

Three CTCL patient cases, each with an expert commentary, cover:

- Disease staging and risk stratification, and the importance of gaining multicompartamental control
- The prognostic relevance of blood involvement and its implications for monitoring and treatment
- Guidance on treatment selection and sequencing in CD30-expressing CTCL, including a benefit–risk assessment

Target audience

This activity is intended for dermatologists, onco dermatologists, hemato oncologists, pathologists, primary care physicians, and other healthcare professionals interested in the treatment and management of CTCL engaged in the care of patients with CTCL.

Educational objectives

After completing this activity, the participant should be better able to:

- **Recognize** the multicompartamental nature of mycosis fungoides and Sézary syndrome and the classification challenges of CTCL
- **Explain** the importance of blood classification in disease staging and methods of measurement of blood involvement
- **Apply** a stage-based approach to treatment selection using novel antibody-based agents for patients with advanced-stage CTCL
- **Implement** individualized evidence-based treatment plans for the optimal clinical management of patients with advanced-stage CTCL

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the

Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician continuing medical education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period March 10, 2021, through March 10, 2022:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Complete the three interactive patient case activities
3. Take the post-activity test and complete the evaluation
4. Download the certificate of CME credit

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty	Relationship identified with:
Ellen J. Kim, MD	Consultant for Almirall, Galderma, and Helsinn. Contracted researcher for Galderma, Innate Pharma, and Soligenix.
Steven M. Horwitz, MD	Consultant for ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Kirin, Myeloid Therapeutics, Seagen Inc., Takeda,

	Trillium Therapeutics, Verastem Oncology, and Vividion Therapeutics. Contracted researcher for ADC Therapeutics, Affimed, Aileron Therapeutics, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Kirin, Millennium/Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem Oncology.
Larisa J. Geskin, MD, FAAD	Consultant for Helsinn, Mallinckrodt Pharmaceuticals, Kyowa Kirin, Regeneron, Sanofi. Speakers bureau for Helsinn. Contracted researcher for Helsinn, Kyowa Kirin, and Innate Pharma.

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Kyowa Kirin, Inc. and Seattle Genetics, Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

info@ologyeducation.org, www.ologyeducation.org

inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Media

Internet